Clinical trial

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

NCT00510718

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-07-23

PhasePHASE1

Study timeline

Study start (actual)2007-07-23Date precision: day

Registry last updated2019-10-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Hormone Refractory Prostate Cancerunresolved

Interventions

MDV3100DRUG

Sponsors & collaborators

Pfizerlead sponsor

Astellas Pharma Inccollaborator

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.collaborator

Mapped research locations

New YorkNew York, United States2 HoustonTexas, United States2 BostonMassachusetts, United States2 SeattleWashington, United States2 PortlandOregon, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00510718 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.